Trial Details
COMPLETEDBasic Information
| Clinical ID | c192 |
|---|---|
| Identifier | NCT00073047 |
| Trial Title | Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NO |
|---|---|
| Conditions | Ulcerative Colitis|Gastrointestinal Disease|Inflammatory Bowel Disease |
| Interventions | DRUG: Daclizumab |
Participant Information
| Sponsor | Facet Biotech |
|---|---|
| City | Huntsville |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | CHILD, ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE2 |
Time Information
| Start Date | 2025-04-03 |
|---|---|
| Primary Completion Date | - |
| Completion Date | 2025-07-06 |